[{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"b9c34573-0235-40cd-9198-16fe6c36e675","acronym":"HBCH-RT-2021-01","url":"https://clinicaltrials.gov/study/NCT05021328","created_at":"2021-08-25T14:53:25.228Z","updated_at":"2025-02-25T16:32:34.697Z","phase":"Phase 1","brief_title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","source_id_and_acronym":"NCT05021328 - HBCH-RT-2021-01","lead_sponsor":"Hubei Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 02/05/2025","primary_completion_date":" 02/05/2025","study_txt":" Completion: 02/05/2025","study_completion_date":" 02/05/2025","last_update_posted":"2025-02-07"},{"id":"829b11a8-2149-49a1-8445-bba09c622fc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06739395","created_at":"2025-02-26T09:10:09.582Z","updated_at":"2025-02-26T09:10:09.582Z","phase":"Phase 2","brief_title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","source_id_and_acronym":"NCT06739395","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-12-18"},{"id":"2d9a8f08-c565-475d-9d28-781aa1dd5529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06662006","created_at":"2025-02-26T07:54:41.562Z","updated_at":"2025-02-26T07:54:41.562Z","phase":"Phase 2","brief_title":"Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT06662006","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-10-28"},{"id":"5822d0ef-f563-4c59-8353-4d50af33551c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06456138","created_at":"2024-06-15T04:06:37.221Z","updated_at":"2025-02-25T15:45:39.816Z","phase":"Phase 1/2","brief_title":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","source_id_and_acronym":"NCT06456138","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"a0d0e389-447c-4476-ad0f-b6fe4f94829c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06429397","created_at":"2024-05-28T20:34:54.364Z","updated_at":"2024-07-02T16:35:00.861Z","phase":"Phase 2","brief_title":"First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study","source_id_and_acronym":"NCT06429397","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/20/2024","primary_completion_date":" 05/20/2024","study_txt":" Completion: 05/28/2026","study_completion_date":" 05/28/2026","last_update_posted":"2024-05-27"},{"id":"e6172513-2364-4de6-bf15-1396ec0fffe6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04967079","created_at":"2021-07-19T14:52:35.810Z","updated_at":"2024-07-02T16:35:08.058Z","phase":"Phase 1","brief_title":"Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients","source_id_and_acronym":"NCT04967079","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Focus V (anlotinib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 03/26/2024","study_completion_date":" 03/26/2024","last_update_posted":"2024-04-23"},{"id":"0f2198ed-12a6-4300-b49a-f4eb9638b583","acronym":"","url":"https://clinicaltrials.gov/study/NCT06367010","created_at":"2024-04-16T14:31:25.387Z","updated_at":"2024-07-02T16:35:09.496Z","phase":"","brief_title":"Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients","source_id_and_acronym":"NCT06367010","lead_sponsor":"Jiangxi Provincial Cancer Hospital","biomarkers":" CEACAM5 • TG","pipe":"","alterations":" ","tags":["CEACAM5 • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-04-16"},{"id":"d7c1dd23-b592-49e2-9ffb-7f723f3c6b6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010901","created_at":"2023-08-25T15:08:21.904Z","updated_at":"2024-07-02T16:35:22.516Z","phase":"Phase 1","brief_title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","source_id_and_acronym":"NCT06010901","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/13/2024","start_date":" 01/13/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-23"},{"id":"4058c033-e7dd-44c8-90ff-3840e3d6f95b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03646968","created_at":"2021-01-18T17:54:06.485Z","updated_at":"2024-07-02T16:35:25.181Z","phase":"Phase 2","brief_title":"Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study","source_id_and_acronym":"NCT03646968","lead_sponsor":"Yongchang Zhang","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Focus V (anlotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-12-27"},{"id":"6d17eabe-16d8-4590-8d9b-337ef0855fd7","acronym":"ZL-IRIAN","url":"https://clinicaltrials.gov/study/NCT05229003","created_at":"2022-02-09T17:52:48.648Z","updated_at":"2024-07-02T16:35:27.176Z","phase":"Phase 2","brief_title":"Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC","source_id_and_acronym":"NCT05229003 - ZL-IRIAN","lead_sponsor":"Fudan University","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • irinotecan • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2022","start_date":" 03/09/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-05"},{"id":"3c122a57-64c7-4f22-9200-96eb6ce846d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04854668","created_at":"2021-04-22T20:53:33.067Z","updated_at":"2024-07-02T16:35:27.423Z","phase":"Phase 3","brief_title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04854668","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 748","initiation":"Initiation: 07/30/2020","start_date":" 07/30/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-01"},{"id":"c8a6eedc-1ed1-4875-af01-24ea45544955","acronym":"","url":"https://clinicaltrials.gov/study/NCT02584478","created_at":"2021-04-02T17:53:19.822Z","updated_at":"2024-07-02T16:35:29.963Z","phase":"Phase 3","brief_title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","source_id_and_acronym":"NCT02584478","lead_sponsor":"Advenchen Laboratories, LLC","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Focus V (anlotinib) • pegylated liposomal doxorubicin • topotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 294","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-08"},{"id":"d1f4bcce-87a9-4c04-80d4-09aca4591ab9","acronym":"NeoSACT","url":"https://clinicaltrials.gov/study/NCT04877821","created_at":"2023-09-13T20:13:19.164Z","updated_at":"2024-07-02T16:35:29.896Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC","source_id_and_acronym":"NCT04877821 - NeoSACT","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-08"},{"id":"d4ccf9a1-cfe3-49ca-b888-1b629d81e7d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06086197","created_at":"2023-10-17T15:12:39.565Z","updated_at":"2024-07-02T16:35:31.261Z","phase":"Phase 2","brief_title":"A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL","source_id_and_acronym":"NCT06086197","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • Focus V (anlotinib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-30"},{"id":"6f742877-39f1-45fb-91cd-0b77705ead8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102928","created_at":"2023-10-26T15:14:21.989Z","updated_at":"2024-07-02T16:35:31.601Z","phase":"","brief_title":"A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation","source_id_and_acronym":"NCT06102928","lead_sponsor":"Kunming Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-10-26"},{"id":"25d1d2ef-8b05-439f-8036-2b246d7da6fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05296577","created_at":"2022-03-26T00:55:00.641Z","updated_at":"2024-07-02T16:35:35.925Z","phase":"Phase 2","brief_title":"Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT05296577","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • vinorelbine tartrate"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-09-25"},{"id":"ae320701-a2f3-4b67-bf24-14787948f6b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119674","created_at":"2023-09-21T23:10:55.176Z","updated_at":"2024-07-02T16:35:35.964Z","phase":"Phase 1/2","brief_title":"Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT04119674","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • BRAF","pipe":"","alterations":" ","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 08/23/2022","primary_completion_date":" 08/23/2022","study_txt":" Completion: 08/23/2022","study_completion_date":" 08/23/2022","last_update_posted":"2023-09-22"},{"id":"288c4f76-3df6-413f-bc79-bddb29118d57","acronym":"","url":"https://clinicaltrials.gov/study/NCT06048315","created_at":"2023-09-21T14:10:48.638Z","updated_at":"2024-07-02T16:35:36.259Z","phase":"Phase 3","brief_title":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody","source_id_and_acronym":"NCT06048315","lead_sponsor":"Degan Lu","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-09-21"},{"id":"abcd5270-c32a-4e5e-9f9c-f76866979d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043973","created_at":"2023-09-21T15:10:34.200Z","updated_at":"2024-07-02T16:35:36.485Z","phase":"Phase 3","brief_title":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","source_id_and_acronym":"NCT06043973","lead_sponsor":"Qianfoshan Hospital","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 mutation • EGFR mutation","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2023-09-21"},{"id":"60707de4-d68b-43d2-b8f8-d68e859d0321","acronym":"","url":"https://clinicaltrials.gov/study/NCT05301764","created_at":"2022-03-31T19:54:37.938Z","updated_at":"2024-07-02T16:35:37.037Z","phase":"Phase 1/2","brief_title":"A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma","source_id_and_acronym":"NCT05301764","lead_sponsor":"Lyvgen Biopharma Holdings Limited","biomarkers":" TMB • MSI • IFNG • IL6 • TNFA • TNFRSF9","pipe":"","alterations":" ","tags":["TMB • MSI • IFNG • IL6 • TNFA • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • exlinkibart (LVGN6051)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 03/19/2025","primary_completion_date":" 03/19/2025","study_txt":" Completion: 10/19/2025","study_completion_date":" 10/19/2025","last_update_posted":"2023-09-14"},{"id":"fe7a5d8e-4b89-442a-960a-83aeeffb3ee8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04790409","created_at":"2021-03-10T13:54:17.167Z","updated_at":"2024-07-02T16:35:37.014Z","phase":"Phase 2","brief_title":"Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations","source_id_and_acronym":"NCT04790409","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Tyvyt (sintilimab)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 09/13/2023","primary_completion_date":" 09/13/2023","study_txt":" Completion: 09/13/2023","study_completion_date":" 09/13/2023","last_update_posted":"2023-09-14"},{"id":"fa87048f-420f-406b-8c99-62a5161df0e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015126","created_at":"2023-08-29T16:10:04.804Z","updated_at":"2024-07-02T16:35:38.733Z","phase":"","brief_title":"Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT06015126","lead_sponsor":"Yan Xue","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-08-29"},{"id":"9c775aca-d2d1-4d7a-a083-a69161d2847e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06000033","created_at":"2023-08-21T15:08:53.251Z","updated_at":"2024-07-02T16:35:39.535Z","phase":"Phase 2","brief_title":"Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer","source_id_and_acronym":"NCT06000033","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-21"}]